VIA
RIGL icon

Virtus Investment Advisers’s Rigel Pharmaceuticals RIGL Stock Holding History

Virtus Investment Advisers’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Buy
35,400
+28,714
+429% +$886K 0.32% 137
2026
Q1 		$181K Buy
6,686
+162
+2% +$5.44K 0.05% 430
2025
Q4 		$279K Buy
+6,524
New +$246K 0.08% 273

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtus Investment Advisers's RIGL Position: Q2 2026 in Review

Virtus Investment Advisers increased its Rigel Pharmaceuticals (RIGL) stake by 429% in Q2 2026, buying an estimated $886K and bringing the position to 35,400 shares worth $1.38M. The position accounts for 0.32% of the portfolio, ranked #137.

Virtus Investment Advisers first reported a position in RIGL in Q4 2025 and has held it in 3 quarters since. 155 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Virtus Investment Advisers held 35,400 shares of Rigel Pharmaceuticals worth $1.38M as of Q2 2026.
  • Virtus Investment Advisers bought 28,714 Rigel Pharmaceuticals shares in Q2 2026, an estimated $886K.
  • Rigel Pharmaceuticals made up 0.32% of Virtus Investment Advisers's portfolio in Q2 2026, its #137 holding.
  • Virtus Investment Advisers first reported a position in Rigel Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 155 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.